2025 (74 POSTS)

Verwiel A, Rish W. 2025. Multidisciplinary perspectives on cumulative impact assessment for vulnerable communities: Expert elicitation using a Delphi method. Integr Environ Assess Manag 21(2):301-313; doi: 10.1093/inteam/vjae051. PMID: 39881570.

View Abstract

Wikoff D. Use cases of strategic application of ML/AI in the risk assessment process. Toxicology Forum 2025 Winter Meeting, Raleigh, NC, February 2025.

Wikoff D. Pragmatic solutions for better using evidence-based methods to integrate observational data in food safety assessments. Toxicology Forum 2025 Winter Meeting, Raleigh, NC, February 2025.

Lagiakos HR, Zou Y, Igawa H, Therrien E, Lawrenz M, Kato M, Svensson M, Gray F, Jensen K, Dahlgren M, Pelletier R, Dingley K, et al. 2025. In silico enabled discovery of KAI-11101, a preclinical DLK inhibitor for the treatment of neurodegenerative disease and neuronal injury. J Med Chem 68(3):2720-2741; doi: 10.1021/acs.jmedchem.4c02074. PMID: 39670820.

View Abstract

Borghoff SJ, Rivera B, Fitch S, Buerger AN, Choksi N, Franzen A, Vincent MJ, Covington T, Bus J, Rushton E, Lea IA. 2025. Systematic evaluation of the evidence base on methyl tert-butyl ether supporting a lack of concern for carcinogenic hazard in human based on animal cancer studies and mechanistic data. Curr Res Toxicol 8:100224; doi: 10.1016/j.crtox.2025.100224. PMID: 40084233.

View Abstract

Rogers JM, Buerger AN, Heintz MM, Palermo CM, Haws LC, Lea IA. 2025. Evaluation of a hypothesized Sertoli cell-based adverse outcome pathway for effects of diisononyl phthalate on the developing testis. Curr Res Toxicol 8:100219; doi: 10.1016/j.crtox.2025.100219. PMID: 40123861.

View Abstract

Lea IA, Buerger AN, Feifarek D, Mihalchik A, Heintz MM, Haws LC, Nyambego H, Goyak K, Palermo C, Borghoff SJ. 2025. Evaluation of the endocrine disrupting potential of Di-isononyl phthalate. Curr Res Toxicol 8:100220; doi: 10.1016/j.crtox.2025.100220. PMID: 40092461. Corrigendum 8:100233; doi: 10.1016/j.crtox.2025.100233; PMID 40529321.

View Abstract

Moyer HL, Vergara L, Stephan C, Sakolish C, Ford LC, Tsai HD, Lin HC, Chiu WA, et al. 2025. Comparative analysis of caco-2 cells and human jejunal and duodenal enteroid-derived cells in gel- and membrane-based barrier models of intestinal permeability. Toxicol Sci 204(2):181-197; doi: 10.1093/toxsci/kfaf011. PMID: 39886939.

View Abstract

Kennedy SB, Heintz MM, Klaren WD, Wikoff DS, Haws LC, Fitch SE. 2025. An integrated ecotoxicological study reliability framework for use in toxicity value development. Environ Tox Chem 44(4):1142-1153; doi: 10.1093/etojnl/vgaf030. PMID: 39873747.

View Abstract

Schaefer HR, Vincent MJ, Burns CJ, Lange SS. 2025. Increasing the utility of epidemiologic studies as key evidence in chemical risk assessment. Toxicol Sci 203(2):166-170; doi: 10.1093/toxsci/kfae134. PMID: 39657235.

View Abstract

Sakolish C, Moyer HL, Tsai HD, Ford LC, Dickey AN, Bajaj P, Villenave R, Hewitt P, et al. 2025. Comparative analysis of the physiological and transport functions of various sources of renal proximal tubule cells under static and fluidic conditions in PhysioMimix T12 platform. Drug Metab Dispos 53(1):10001; doi: 10.1124/dmd.124.001488. PMID: 39884810.

View Abstract

Zilber D, Messier KP, House J, Parham F, Auerbach SS, Wheeler MW. 2025. Bayesian gene set benchmark dose estimation for “omic” responses. Bioinformatics 41(1):btaf008; doi: 10.1093/bioinformatics/btaf008. PMCID: PMC11783320.

View Abstract

Rana Z, Frankenfeld CL, Kennedy E, Bertoldi J, de Jonge E, Cheskin L. 2025. Food sources of energy and nutrients among US college students: The Health Starts Here cohort study. J Am Coll Health 73(1):301-310; doi: 10.1080/07448481.2023.2220397. PMID: 37290009.

View Abstract

Lipworth L, Panko JM, Allen BC, Mumma MT, Jiang X, Vincent MJ, Bare JL, Antonijevic T, Vivanco SN, Marano DE, Suh M, Cohen S, Mittal L, Proctor DM. 2025. Lung cancer mortality among aircraft manufacturing workers with long-term, low-level, hexavalent chromium exposure. J Occup Environ Hyg 22(3):214-227; doi: 10.1080/15459624.2024.2439817. PMID: 39773194.

View Abstract

2024 (138 POSTS)

Kim A, Cong Z, Jazieh A-R, Church TR, Reichert H, Nicholson G, Fryzek J, Cohen SS. 2024. Estimating the incremental population health impact of a multi-cancer early detection (MCED) test to complement existing screening among elevated risk populations with multiple cancer risk factors: A mathematical modeling study. BMC Health Serv Res 24(1):1584; doi: 10.1186/s12913-024-12037-1. PMID: 39695574.

View Abstract

Munn Z, Pollock D, Stone J, Hasanoff S, Gordon A, Price C, et al. 2024. The impact of using cannabis during pregnancy on the infant and mother: An overview of systematic reviews, evidence map, targeted updates, and de novo synthesis. Austral NZ J Obstet Gynaecol; doi: 10.1111/ajo.13916. Online ahead of print, December 19, 2024.

View Abstract

Olaye A, Bean K, Velikanova R, Wolters S, Miller B, Jensen I, Pang F. Cost-effectiveness of atidarsagene autotemcel (ARSA-CEL) gene therapy for treating metachromatic leukodystrophy (MLD) in Ireland, Belgium, and the Netherlands as a part of the Beneluxa Initiative. Abstract EE693, ISPOR Europe 2024, November 2024.

View Abstract

Haselkorn T, Hughes W, Lennox A, Schara-Schmidt U, Roca A, Miller B, Jensen I, et al. Real-world impact of X-linked myotubular myopathy (XLMTM) on caregivers in the United Kingdom (UK), Germany, and Spain. Abstract PCR257, ISPOR EU 2024 (Top 5% Finalist).

View Abstract

Schaefer H. Cadmium–Initiatives to reduce dietary exposure. Society for Risk Analysis Annual Meeting, Austin, TX, 2024.

Xue Y, Wang L, Huo R, Chen M, Melo B, Dingley K, et al. 2024. 1β-Hydroxydeoxycholic acid as an endogenous biomarker in human plasma for assessment of CYP3A clinical drug-drug interaction potential. Drug Metab Dispos 52(9):966–974; doi: 10.1124/dmd.124.001680. PMID: 38991779.

View Abstract